Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response

References

• ChooQLKuoGWeinerAJOverbyLRBradleyDWHoughtonMScience198924449023593622523562
   PubMed Web of Science ®Google Scholar
• ChoojitrWRuangkrisTSurgical wound infections in gynaecology at Rajvithi Hospital 1989–1990J Med Assoc Thai199578Suppl 2S78S807561600
   PubMedGoogle Scholar
• SeeffLBNatural history of hepatitis CAm J Med19991076B10S15S
   PubMedGoogle Scholar
• SeeffLBDilemma of the natural history of hepatitis CJ Gastroenterol Hepatol199914319920110197486
   PubMedGoogle Scholar
• HallidayJKlenermanPBarnesEVaccination for hepatitis C virus: closing in on an evasive targetExpert Rev Vaccines201110565967221604986
   PubMed Web of Science ®Google Scholar
• ScheelTKRiceCMUnderstanding the hepatitis C virus life cycle paves the way for highly effective therapiesNat Med201319783784923836234
   PubMed Web of Science ®Google Scholar
• WendtAAdhouteXCastellaniPChronic hepatitis C: future treatmentClin Pharmacol2014611724470777
   PubMedGoogle Scholar
• WeinerAJBrauerMJRosenblattJVariable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteinsVirology199118028428481846505
   PubMedGoogle Scholar
• HoughtonMWeinerAHanJKuoGChooQLMolecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral diseaseHepatology19911423813881650328
   PubMed Web of Science ®Google Scholar
• GrakouiAWychowskiCLinCFeinstoneSMRiceCMExpression and identification of hepatitis C virus polyprotein cleavage productsJ Virol1993673138513957679746
   PubMed Web of Science ®Google Scholar
• GrakouiAMcCourtDWWychowskiCFeinstoneSMRiceCMA second hepatitis C virus-encoded proteinaseProc Natl Acad Sci U S A1993902210583105878248148
   PubMed Web of Science ®Google Scholar
• LiuCLiuWYangJFangDHCV core protein activates expression of vascular endothelial growth factor in HepG(2) cellsZhonghua Gan Zang Bing Za Zhi200194214216 Chinese11602051
   PubMedGoogle Scholar
• FeinstoneSMHuDJMajorMEProspects for prophylactic and therapeutic vaccines against hepatitis C virusClin Infect Dis201255Suppl 1S25S3222715210
   PubMed Web of Science ®Google Scholar
• ArichiTSaitoTMajorMEProphylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse modelProc Natl Acad Sci U S A200097129730210618412
   PubMed Web of Science ®Google Scholar
• HungCFMaBMonieATsenSWWuTCTherapeutic human papillomavirus vaccines: current clinical trials and future directionsExpert Opin Biol Ther20088442143918352847
   PubMed Web of Science ®Google Scholar
• Le CorrePRyttingJHGajanVChevanneFLe VergeRIn vitro controlled release kinetics of local anaesthetics from poly(d,l-lactide) and poly(lactide-co-glycolide) microspheresJ Microencapsul19971422432559132474
   PubMed Web of Science ®Google Scholar
• JeonHJJeongYIJangMKParkYHNahJWEffect of solvent on the preparation of surfactant-free poly(d,l-lactide-co-glycolide) nanoparticles and norfloxacin release characteristicsInt J Pharm20002071–29910811036235
   PubMedGoogle Scholar
• ShenHAckermanALCodyVEnhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticlesImmunology20061171788816423043
   PubMed Web of Science ®Google Scholar
• SharmaCKhanMAMohanTShrinetJLathaNSinghNA synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancerImmunol Res201458113213824174302
   PubMedGoogle Scholar
• RaimondiSBrunoSMondelliMUMaisonneuvePHepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysisJ Hepatol20095061142115419395111
   PubMed Web of Science ®Google Scholar
• BrunoSCrosignaniAMaisonneuvePRossiSSiliniEMondelliMUHepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort studyHepatology20074651350135617680653
   PubMed Web of Science ®Google Scholar
• LiuJZhuLZhangXExpression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteinsBiotechnol Appl Biochem200134Pt 210911911592917
   PubMedGoogle Scholar
• LinCKKaluntaCIChenFSNguyenTTKapteinJSLadPMDimethyl sulfoxide suppresses apoptosis in Burkitt’s lymphoma cellsExp Cell Res199521624034107843285
   PubMedGoogle Scholar
• AlineFBrandDPierreJDendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccinationVaccine200927385284529119450633
   PubMed Web of Science ®Google Scholar
• ZhengYZhangYMaYWanJShiCHuangLEnhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular regionJ Microbiol200846672873619107404
   PubMedGoogle Scholar
• KatareYKPandaAKImmunogenicity and lower dose requirement of polymer entrapped tetanus toxoid co-administered with alumVaccine200624173599360816513224
   PubMedGoogle Scholar
• DiwanMElamanchiliPCaoMSamuelJDose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle deliveryCurr Drug Deliv20041440541216305402
   PubMedGoogle Scholar
• DementoSLSiefertALBandyopadhyayASharpFAFahmyTMPathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccinesTrends Biotechnol201129629430621459467
   PubMed Web of Science ®Google Scholar
• NewmanKDSosnowskiDLKwonGSSamuelJDelivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responsesJ Pharm Sci19988711142114279811500
   PubMedGoogle Scholar
• HamdySHaddadiAHungRWLavasanifarATargeting dendritic cells with nano-particulate PLGA cancer vaccine formulationsAdv Drug Deliv Rev20116310–1194395521679733
   PubMed Web of Science ®Google Scholar
• Kovacsovics-BankowskiMClarkKBenacerrafBRockKLEfficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophagesProc Natl Acad Sci U S A19939011494249468506338
   PubMed Web of Science ®Google Scholar
• PaluckaKBanchereauJDendritic-cell-based therapeutic cancer vaccinesImmunity2013391384823890062
   PubMed Web of Science ®Google Scholar
• AlonsoMJGuptaRKMinCSiberGRLangerRBiodegradable microspheres as controlled-release tetanus toxoid delivery systemsVaccine19941242993068178550
   PubMed Web of Science ®Google Scholar
• OyewumiMOKumarACuiZNano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responsesExpert Rev Vaccines2010991095110720822351
   PubMed Web of Science ®Google Scholar
• BoehmUKlampTGrootMHowardJCCellular responses to interferon-gammaAnnu Rev Immunol1997157497959143706
   PubMed Web of Science ®Google Scholar
• WhitmireJKTanJTWhittonJLInterferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infectionJ Exp Med200520171053105915809350
   PubMed Web of Science ®Google Scholar
• MocikatRBraumullerHGumyANatural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responsesImmunity200319456156914563320
   PubMed Web of Science ®Google Scholar